Do you want to read an article? Please log in or register.
Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial
Migraine and Headache
RECOMMENDED
Related content
RECOMMENDED
Migraine and Headache
Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study)
Cephalalgia.
Brandes JL, Klise S, Krege JH, Case M, Khanna R, Vasudeva R, Raskin J, Pearlman EM, Kudrow D
doi: 10.1177/0333102419864132.
RECOMMENDED
Migraine and Headache
Ubrogepant, an Acute Treatment for Migraine, Improved Patient-Reported Functional Disability and Satisfaction in 2 Single-Attack Phase 3 Randomized Trials, ACHIEVE I and II
★ 2
Recommended by
Prof. Dr Christian Kamm, Faculty Member
★ 3
Recommended by
Prof. Dr Claudio Gobbi, Faculty Member
Headache.
Dodick DW, Lipton RB, Ailani J, Halker Singh RB, Shewale AR, Zhao S, Trugman JM, Yu SY, Viswanathan HN
doi: 10.1111/head.13766.
RECOMMENDED
Migraine and Headache
Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial
★ 2
Recommended by
Prof. Dr Christian Kamm, Faculty Member
JAMA.
Lipton RB, Dodick DW, Ailani J, Lu K, Finnegan M, Szegedi A, Trugman JM
doi: 10.1001/jama.2019.16711.
RECOMMENDED
Migraine and Headache
Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial
Lancet.
Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG, Coric V, Lipton RB
doi: 10.1016/S0140-
Migraine and Headache
A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine
BMC Neurol.
Camporeale A, Kudrow D, Sides R, Wang S, Van Dycke A, Selzler KJ, Stauffer VL
doi: 10.1186/s12883-018-1193-2.
Migraine and Headache
STOP 301: A Phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD® ) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients
Headache
Smith TR, Winner P, Aurora SK, Jeleva M, Hocevar-Trnka J, Shrewsbury SB
doi: 10.1111/head.14184
Migraine and Headache
Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensions
Cephalalgia.
Ashina M, Kudrow D, Reuter U, Dolezil D, Silberstein S, Tepper SJ, Xue F, Picard H, Zhang F, Wang A, Zhou Y, Hong F, Klatt J, Mikol DD
doi: 10.1177/0333102419888222.
Epilepsy
Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307
Epilepsia.
Krauss GL, Perucca E, Kwan P, Ben-Menachem E, Wang XF, Shih JJ, Patten A, Yang H, Williams B, Laurenza A
doi: 10.1111/epi.14044.
RECOMMENDED
Migraine and Headache
Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study
Neurology.
Kuca B, Silberstein SD, Wietecha L, Berg PH, Dozier G, Lipton RB; COL MIG-301 Study Group
doi: 10.1212/WNL.